Inflammatory bowel diseases, most commonly categorized as Crohn's disease and
ulcerative colitis, are immune mediated chronic inflammatory disorders of the …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

Introduction: Fifty years after the discovery of Δ9-tetrahydrocannabinol (THC) as the
psychoactive component of Cannabis, we are assessing the possibility of translating this …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Background We investigated, for the first time, levels of compliance with faecal calprotectin
test in inflammatory bowel disease patients. Methods All consecutive adult inflammatory …

Background Biologically naïve patients with inflammatory bowel disease treated with
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …

ABSTRACT Introduction: Blockers of IL-12/23, as well as specific blockers of IL-23, have
been investigated as options for medical therapy in inflammatory bowel disease. These …

Vedolizumab (VDZ) is a new biological agent which was recently approved for the treatment
of inflammatory bowel disease (IBD) 1 following the good clinical responses reported by …

Inflammatory bowel disease (IBD) is a chronic and relapsing disorder for many people
associated with poor health. Although there are some clinical drugs for IBD treatment, the …

Background The effectiveness of vedolizumab in real-world practice is under evaluation,
while its role in inflammatory bowel disease-associated spondyloarthritis is still unclear …